Larimar Therapeutics Inc represents a strong commitment to developing innovative treatments for rare diseases. The company's corporate philosophy revolves around patient-centered care, scientific excellence, and collaboration. With a focus on precision medicine, Larimar Therapeutics Inc strives to improve the lives of individuals affected by rare genetic disorders. Through its dedication to research and development, the company aims to provide effective therapies that address the underlying cause of these diseases. Larimar Therapeutics Inc's vision is to redefine the standard of care and make a meaningful impact in the field of rare diseases.

Larimar Therapeutics Inc is primarily present in the United States.

Larimar Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2021, raising substantial capital to fund its research and development efforts. Larimar Therapeutics Inc also established key collaborations with leading industry partners to advance its gene therapy programs for treating rare diseases. Furthermore, the company has made significant progress in its lead product candidate, CTI-1601, for treating Friedreich's ataxia, a rare genetic disease. Larimar Therapeutics Inc's dedication to developing innovative therapies and its strategic partnerships have positioned the company as a promising player in the biotechnology sector.

Larimar Therapeutics Inc., founded in [insert year], is a biotechnology company specializing in gene therapies for rare diseases. The company's mission is to develop innovative treatments that address the underlying genetic causes of these conditions. Larimar Therapeutics Inc. has a strong focus on utilizing its proprietary gene-manipulation platform to design and deliver highly targeted therapies. By leveraging cutting-edge technologies, the company aims to improve the lives of patients with limited or no treatment options. Larimar Therapeutics Inc. continues to collaborate with leading academic institutions and pharmaceutical partners to accelerate the development of novel gene therapies and make a meaningful impact in the field of rare disease treatment.

The main competitors of Larimar Therapeutics Inc in the market include other companies in the biopharmaceutical sector, such as Amicus Therapeutics, Inc., REGENXBIO Inc., and Sangamo Therapeutics, Inc. These companies also focus on developing innovative therapies for rare genetic diseases and disorders. Larimar Therapeutics Inc distinguishes itself through its proprietary protein replacement platform and dedication to addressing unmet medical needs in rare diseases. As Larimar Therapeutics Inc continues to drive advancements in the biopharmaceutical industry, it faces competition with these prominent players who strive for similar scientific and commercial success.

Larimar Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Larimar Therapeutics Inc revolves around developing innovative therapies for treating rare genetic diseases. Larimar Therapeutics focuses on advancing small molecule therapeutics that target RNA using its proprietary Ribonucleic Acid Displacement (RAD) technology. This approach enables the company to modulate the mRNA translation, thereby addressing the underlying genetic cause of the diseases. By leveraging its expertise in drug discovery and development, Larimar Therapeutics aims to improve the lives of patients with rare genetic disorders through the development of targeted and effective treatments.

Az Larimar Therapeutics P/E mutatója -4,64.

Az Larimar Therapeutics KUV 0.

Az AlleAktien Minőségi Score Larimar Therapeutics esetében 3/10.

A Larimar Therapeutics esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Larimar Therapeutics nyereség -84,99 Mió. USD.

Larimar Therapeutics Inc is a biotechnology company that focuses on developing therapies for rare genetic diseases. The company utilizes modern technologies to improve treatment options for patients with rare genetic diseases who often have limited options for treating their condition. The business model of Larimar Therapeutics consists of four main areas: 1. Research and development: Larimar Therapeutics invests in the development of new therapies for rare genetic diseases. The company collaborates closely with leading scientists and clinics to develop and test new treatment possibilities. 2. Partnerships: Larimar Therapeutics aims to establish partnerships with other biotechnology and pharmaceutical companies to achieve greater reach and leverage research opportunities together. 3. Licensing: The company works with licensing technologies and products to develop new treatment options for rare genetic diseases. 4. Distribution: In terms of creating distribution channels, the company, as a biotechnology company, is not directly responsible. The end product developed by the company must be made available to an independent distributor or distribution company. The products of Larimar Therapeutics include therapies for rare genetic diseases, including: 1. Friedreich's Ataxia: Friedreich's Ataxia is a neurological metabolic disease that can lead to problems with movement, vision, and speech. Larimar Therapeutics specializes in the development of drugs targeting the causes of Friedreich's Ataxia. 2. Other inherited diseases: Larimar Therapeutics is working on developing therapies for a range of diseases, including Duchenne muscular dystrophy, Maroteaux-Lamy syndrome, and Mucopolysaccharidosis type IVA. Larimar Therapeutics utilizes state-of-the-art technologies and research methods to ensure the precision, effectiveness, and safety of their therapies while improving cost-effectiveness and the opportunity to make these treatment options accessible to everyone. The company aims to achieve a strong leadership position in the rare diseases field by developing innovative solutions and therapies to improve and enhance the lives of patients in the long term.

A(z) Larimar Therapeutics évente alkalommal oszt ki 0 USD összegű osztalékot.

A Larimar Therapeutics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Larimar Therapeutics ISIN kódja: US5171251003.

A Larimar Therapeutics WKN-je A2P5PP.

Az Larimar Therapeutics tőzsdei rövidítése LRMR.

Az elmúlt 12 hónapban a(z) Larimar Therapeutics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Larimar Therapeutics várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Larimar Therapeutics jelenlegi osztalékhozama .

A(z) Larimar Therapeutics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Larimar Therapeutics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Larimar Therapeutics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Larimar Therapeutics által 2024. 07. 31.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 07. 31.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 07. 31. időpontban történt.

2023 évben a Larimar Therapeutics 0 USD összegű osztalékot fizetett ki.

Az Larimar Therapeutics osztalékait USD fizeti ki.